Phase 2 HER2-negative Breast Cancer Clinical Trials
38 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 38 trials
Recruiting
Phase 2
Capecitabine in ER+/HER2-negative Breast Cancer
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
University Health Network, Toronto15 enrolled1 locationNCT07631052
Recruiting
Phase 1Phase 2
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Kristina A. Fanucci65 enrolled1 locationNCT07198724
Recruiting
Phase 2
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
Brain Metastasis From Advanced HER2-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT06839560
Recruiting
Phase 2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+2 more
Memorial Sloan Kettering Cancer Center176 enrolled7 locationsNCT07483307
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 2
Sacituzumab Govitecan In TNBC
Triple-Negative Breast CancerHER2-negative Breast CancerInvasive Breast Cancer+2 more
Massachusetts General Hospital260 enrolled5 locationsNCT04230109
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
HER2-negative Breast Cancer
Yale University140 enrolled1 locationNCT06953882
Recruiting
Phase 2
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
HR-positive,HER2-negative Breast Cancer
RenJi Hospital55 enrolled1 locationNCT07396324
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619
Recruiting
Phase 2
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Tumor+1 more
SOLTI Breast Cancer Research Group96 enrolled15 locationsNCT05982093
Recruiting
Phase 2
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerHormone Receptor-Positive Breast CancerLocoregional Recurrence
Oana Danciu200 enrolled20 locationsNCT05467891
Recruiting
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
Fudan University160 enrolled1 locationNCT06649331
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 2
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+1 more
University of California, Irvine20 enrolled1 locationNCT05524584
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer
University of Wisconsin, Madison13 enrolled1 locationNCT04573231
Recruiting
Phase 2
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
HER2-negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University39 enrolled1 locationNCT07396454